纳斯达克： -- -- --

最近浏览

实时行情

意见反馈

Marinus Pharmaceuticals, Inc.

NASDAQ:MRNS 延时15分钟 已退市
  • 今开：--
    昨收：--
  • 今日区间：--
    52周区间：--
  • 成交量：--
    成交额：--
  • 市 值：--
    市盈率：--
  • 振幅：
    每股收益：
成交量

董事会

Scott N. Braunstein
Scott N. Braunstein currently serves as Independent Director at Caribou Biosciences, Inc. since 2021, Director at One Biosciences SAS starting in 2024, Chief Operating Officer & Director at Stat Medical Services, Inc. since 2010, Director at Rapt Therapeutics, Inc. beginning in 2025, Director at SiteOne Therapeutics, Inc. since 2018, Director at Cornell University College of Agriculture & Life Sciences, Director at BWBC I LLC, Director at Atai Beckley, Inc., and Operating Partner at Aisling Capital LLC since 2015. Former roles include Chairman, President & Chief Executive Officer at Marinus Pharmaceuticals, Inc. from 2022 to 2025, Chairman at ArTara Subsidiary, Inc., Managing Director at JPMorgan Investment Management, Inc. from 2002 to 2014, Independent Director at Esperion Therapeutics, Inc. from 2015 to 2020, Managing Director & Senior Portfolio Manager at JPMorgan Chase & Co. from 2002 to 2014, Director at Alaunos Therapeutics, Inc. from 2018 to 2020, Independent Director at Constellation Pharmaceuticals, Inc. from 2019 to 2021, Independent Director at Protara Therapeutics, Inc. from 2018 to 2020, Lead Independent Director at Trevena, Inc. from 2024 to 2025, Director at Bent Water Brewing Corp., Principal at Deutsche Bank AG from 2000 to 2002, Vice President-Operations at Cello Health BioConsulting Inc. from 1999 to 2000, Chief Operating Officer at Pacira Biosciences, Inc. from 2017 to 2018, Assistant Clinical Professor at Columbia University Irving Medical Center, Assistant Clinical Professor at Albert Einstein College of Medicine, Inc. from 1993 to 1994, Portfolio Manager at EverPoint Asset Management LLC from 2014 to 2015, Physician at Summit Medical Group LLC, Portfolio Manager at JPMorgan Global Healthcare Fund, and Member-Supervisory Board at Atai Beckley NV. Education includes a doctorate degree conferred in 1990 from Albert Einstein College of Medicine, Inc.
Tim M. Mayleben
Tim M. Mayleben is the founder of Esperance BioVentures LLC, which was founded in 1998. He is currently the Lead Independent Director at Marinus Pharmaceuticals, Inc. since 2008 and a Director at Wolverine Venture Fund. Previously, he served as the President, Chief Executive Officer & Director of Esperion Therapeutics, Inc. from 2010 to 2021. He also held positions as the Non-Executive Chairman of Kaleo, Inc., Director of Aksys Ltd., Director of Vericel Corp., Director of Rubicon Genomics, Inc., President, Chief Operating Officer & Director of NightHawk Radiology Holdings, Inc., Director of Solulink, Inc., Director of Lycera Corp., and Independent Director of Loxo Oncology, Inc. from 2015 to 2019. Additionally, he is currently an Independent Director at Landos Biopharma, Inc. from 2021 to 2024. He previously served as the Chief Operating & Financial Officer of Esperion Therapeutics, Inc. from 1998 to 2004. He also held positions at Applied Intelligent Systems, Inc. and Transom Technologies, Inc. Furthermore, he is an Advisory Board Member of Michigan Ross Zell Lurie Institute. Mr. Mayleben received his undergraduate degree from Stephen M. Ross School of Business in 1984 and his MBA from Kellogg School of Management in 1997.
Seth H. Z. Fischer
Seth H. Z. Fischer is currently an Independent Director at Marinus Pharmaceuticals, Inc., Esperion Therapeutics, Inc., and Milestone Pharmaceuticals, Inc. He is also an Advisor at Healthquest Capital Management Co LLC. Previously, he served as the Chief Executive Officer & Director at VIVUS, Inc. from 2013 to 2017. He was the Group Chairman at Biosense Webster, Inc. from 2008 to 2012 and at North American Pharmaceuticals Co. from 2004 to 2007. He also held the position of Chairman-Worldwide Franchise at Cordis Corp. from 2008 to 2012. From 1983 to 2012, he was the Group Chairman at Johnson & Johnson. Additionally, he served as the Chairman & President at Ortho-McNeil Pharmaceutical LLC from 2000 to 2004. He has also held director positions at BioSig Technologies, Inc., Trius Therapeutics, Inc., and Spectrum Pharmaceuticals, Inc. He is currently the Lead Independent Director at Agile Therapeutics, Inc. Mr. Fischer obtained his undergraduate degree from The Ohio University in 1977.
旧服务已下线，请迁移至 http://api.fanyi.baidu.com
Scott N. Braunstein
Scott N. Braunstein currently serves as Independent Director at Caribou Biosciences, Inc. since 2021, Director at One Biosciences SAS starting in 2024, Chief Operating Officer & Director at Stat Medical Services, Inc. since 2010, Director at Rapt Therapeutics, Inc. beginning in 2025, Director at SiteOne Therapeutics, Inc. since 2018, Director at Cornell University College of Agriculture & Life Sciences, Director at BWBC I LLC, Director at Atai Beckley, Inc., and Operating Partner at Aisling Capital LLC since 2015. Former roles include Chairman, President & Chief Executive Officer at Marinus Pharmaceuticals, Inc. from 2022 to 2025, Chairman at ArTara Subsidiary, Inc., Managing Director at JPMorgan Investment Management, Inc. from 2002 to 2014, Independent Director at Esperion Therapeutics, Inc. from 2015 to 2020, Managing Director & Senior Portfolio Manager at JPMorgan Chase & Co. from 2002 to 2014, Director at Alaunos Therapeutics, Inc. from 2018 to 2020, Independent Director at Constellation Pharmaceuticals, Inc. from 2019 to 2021, Independent Director at Protara Therapeutics, Inc. from 2018 to 2020, Lead Independent Director at Trevena, Inc. from 2024 to 2025, Director at Bent Water Brewing Corp., Principal at Deutsche Bank AG from 2000 to 2002, Vice President-Operations at Cello Health BioConsulting Inc. from 1999 to 2000, Chief Operating Officer at Pacira Biosciences, Inc. from 2017 to 2018, Assistant Clinical Professor at Columbia University Irving Medical Center, Assistant Clinical Professor at Albert Einstein College of Medicine, Inc. from 1993 to 1994, Portfolio Manager at EverPoint Asset Management LLC from 2014 to 2015, Physician at Summit Medical Group LLC, Portfolio Manager at JPMorgan Global Healthcare Fund, and Member-Supervisory Board at Atai Beckley NV. Education includes a doctorate degree conferred in 1990 from Albert Einstein College of Medicine, Inc.
Elan Z. Ezickson
Elan Z. Ezickson currently works at Marinus Pharmaceuticals, Inc., as Independent Director from 2019, The Greater Boston Food Bank, as Director, Carmine Therapeutics Pte Ltd., as Director, Asylia Therapeutics, Inc., as Co-President & Director, Nirogy Therapeutics, Inc., as Director, and Carmine Therapeutics, Inc., as Director from 2019. Mr. Ezickson also formerly worked at Sporos Bioventures, Inc., as Chief Executive Officer & Director from 2020 to 2021, Alaunos Therapeutics, Inc., as Independent Director from 2018 to 2020, Tvardi Therapeutics, Inc., as Director, Biogen MA, Inc., as Associate General Counsel in 1996, Biogen, Inc., as President-Biogen Canada from 1994 to 2003, Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC, as Attorney, AVEO Pharmaceuticals, Inc., as Chief Operating Officer & Executive Vice President from 2012 to 2013, Biogen Canada, Inc., as President from 1994 to 2003, and Scholar Rock Holding Corp., as COO & Head-Corporate Development from 2017 to 2018. Mr. Ezickson received his undergraduate degree in 1984 from Yale University and graduate degree in 1988 from Columbia Law School.
Christine Berni Silverstein
Christine Berni Silverstein is currently an Independent Director at Abeona Therapeutics, Inc. and Marinus Pharmaceuticals, Inc. She is also a Member of the National Investor Relations Institute, Women in Bio, Inc., and Project 1972, Inc. In addition, she is the Chief Financial Officer at Artios Pharma Ltd. starting in 2024. Previously, she worked as a Managing Director at SCO Financial Group LLC. She was also the Director-Investor Relations at Relmada Therapeutics, Inc. from 2014 to 2016. From 2021 to 2024, she served as the Chief Financial Officer at Excision BioTherapeutics, Inc. Prior to that, she held the position of Chief Financial Officer at Emendo Biotherapeutics, Inc. from 2020 to 2021. Ms. Silverstein obtained her undergraduate degree from the Peter J. Tobin College of Business.
Marvin H. Johnson
Marvin H. Johnson is currently serving as the Vice Chairman-Trustees Board at Tabor Children's Services since 2014. He is also an Independent Director at Marinus Pharmaceuticals, Inc. since 2023. Previously, he worked as an Independent Director at Trevena, Inc. from 2021 to 2024 and as the Chief Learning Officer at Merck & Co., Inc. from 2016 to 2018. Mr. Johnson completed his undergraduate degree at The Pennsylvania State University.